SSTNIV, a syndecan-1-targeting peptide chimera, reverses immune suppression and inhibits myeloma progression
's potent anti-myeloma activity and support its potential as a promising therapeutic strategy for advanced and relapsed/refractory MM.
Authors
- Oisun Jung (ORCID: https://orcid.org/0000-0002-4099-6274)
- DeannaLee M. Beauvais (ORCID: https://orcid.org/0000-0003-4575-1564)
- Alan C. Rapraeger (ORCID: https://orcid.org/0000-0003-1719-3286)
- Suyong Choi
- Gavril L. Ibaan
- Colin C. Wooldrik
- Jing Zhang (ORCID: https://orcid.org/0009-0001-0147-3315)
- Evan Flietner
Institutions
- Nebraska Medical Center (US)
- University of Wisconsin–Madison (US)
- Norcliffe Foundation (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Signal Transduction and Targeted Therapy
- Published
- 2026-05-12
- DOI
- https://doi.org/10.1038/s41392-026-02709-1
- Primary Topic
- Proteoglycans and glycosaminoglycans research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Multiple Myeloma Research Foundation
- National Cancer Institute
- National Institute of General Medical Sciences